Citations

Clear

3485 citation(s) found for "Sy, Sarah".

Phase I Study of PSMA-Targeted Docetaxel-Containing Nanoparticle BIND-014 in Patients with Advanced Solid Tumors
Hoff, Daniel D. Von , Mita, Monica , Ramanathan, Ramesh K., Mita, Alain C. , LoRusso, Patricia , Burris, Howard A. , Hart, Lowell L., Low, Susan C. , Parsons, Donald M., Zale, Stephen E., Summa, Jason M., Youssoufian, Hagop , Sachdev, Jasgit C. , Weiss, Glen J.

Mayo Clinic

Clinical Cancer Research | February 4, 2016 | Volume: 22 | Issue: 13 | Pages: 3157-3163

10.1158/1078-0432.ccr-15-2548 | PMID 26847057 Get It

Abstract Purpose: First-in-human phase I trial to determine the safety, pharmacokinetics, and antitumor activity of BIND-014, a novel, tumor prostate-specific membrane antigen (PSMA)–targeted nanoparticle, containing docetaxel. Experimental Design: Patients with advanced solid tumors received BIND-014 every three weeks (n = 28) or weekly (n = 27), with dose levels ranging from 3.5 to 75 mg/m2 and 15 to 45 mg/m2, respectively. Results: BIND-014 was generally well tolerated, with no unexpected toxicities. The most common drug-related toxicities (>20% of patients) on either schedule included neutropenia, fatigue, anemia, alopecia, and diarrhea. BIND-014 demonstrated a dose-linear pharmacokinetic profile, distinct from docetaxel, with prolonged persistence of docetaxel-encapsulated circulating nanoparticles. Of the 52 patients evaluable for response, one had a complete response (cervical cancer on the every three week schedule) and five had partial responses (ampullary adenocarcinoma, non–small cell lung, and prostate cancers on the every-three-week schedule, and breast and gastroesophageal cancers on the weekly schedule). Responses were noted in both PSMA-detectable and -undetectable tumors. Conclusions: BIND-014 was generally well tolerated, with predictable and manageable toxicity and a unique pharmacokinetic profile compared with conventional docetaxel. Clinical activity was noted in multiple tumor types. The recommended phase II dose of BIND-014 is 60 mg/m2 every three weeks or 40 mg/m2 weekly. Clin Cancer Res; 22(13); 3157–63. ©2016 AACR.
Analysis of fluid movement in skeletal muscle using fluorescent microspheres
Evertz, Loribeth Q., Greising, Sarah M. , Morrow, Duane A., Sieck, Gary C. , Kaufman, Kenton R. , Sieck, Gary , Kaufman, Kenton R

Mayo Clinic

Muscle & Nerve | February 2, 2016 | Volume: 54 | Issue: 3 | Pages: 444-450

10.1002/mus.25063 | PMID 26833456 Get It

ABSTRACTIntroductionRegional variability in interstitial fluid pressure confounds use of intramuscular pressure measurement to assess muscle force. It is hypothesized that interstitial flow is dependent on intramuscular pressure. The goal of this study was to assess the feasibility of using fluorescent microspheres to evaluate movement of interstitial fluid in skeletal muscle.MethodsTwo diameters of fluorescent microspheres were injected into the rat tibialis anterior during both static (n = 6) and passively lengthened (10% strain) experimental conditions (n = 6). Microsphere dispersion was evaluated using confocal imaging of transverse muscle sections.ResultsFluorescent microspheres tracked interstitial fluid while not penetrating the muscle fiber. When compared with the static condition, significantly greater dispersion (P = 0.003) was seen with passively lengthened conditions (17 ± 9% vs. 31 ± 7%, respectively). Dispersion did not differ for the 2 microsphere sizes (P = 0.811).ConclusionsFluorescent microspheres track movement of interstitial fluid, and dispersion is dependent on passive lengthening. Muscle Nerve 54: 444–450, 2016
Three-Day-Old Boy With Palmar Pustules
Oza, Vikash S. , Asch, Sarah , Mathes, Erin F.

Mayo Clinic

JAMA Pediatrics | February 2, 2016 | Volume: 170 | Issue: 2 | Pages: 171

10.1001/jamapediatrics.2015.1996 | PMID 26830870 Get It

Off-Ice Anaerobic Power Does Not Predict On-Ice Repeated Shift Performance in Hockey
Peterson, Ben , Fitzgerald, John S. , Dietz, Calvin C., Ziegler, Kevin S., Baker, Sarah E. , Snyder, Eric M., Peterson, Ben J, Baker, Sarah E

Mayo Clinic

Journal of Strength and Conditioning Research | January 24, 2016 | Volume: 30 | Issue: 9 | Pages: 2375-2381

10.1519/jsc.0000000000001341 | PMID 26808844 Get It

Abstract Peterson, BJ, Fitzgerald, JS, Dietz, CC, Ziegler, KS, Baker, SE, and Snyder, EM. Off-ice anaerobic power does not predict on-ice repeated shift performance in hockey. J Strength Cond Res 30(9): 2375–2381, 2016—Anaerobic power is a significant predictor of acceleration and top speed in team sport athletes. Historically, these findings have been applied to ice hockey although recent research has brought their validity for this sport into question. As ice hockey emphasizes the ability to repeatedly produce power, single bout anaerobic power tests should be examined to determine their ability to predict on-ice performance. We tested whether conventional off-ice anaerobic power tests could predict on-ice acceleration, top speed, and repeated shift performance. Forty-five hockey players, aged 18–24 years, completed anthropometric, off-ice, and on-ice tests. Anthropometric and off-ice testing included height, weight, body composition, vertical jump, and Wingate tests. On-ice testing consisted of acceleration, top speed, and repeated shift fatigue tests. Vertical jump (VJ) ( r = −0.42; r = −0.58), Wingate relative peak power (WRPP) ( r = −0.32; r = −0.43), and relative mean power (WRMP) ( r = −0.34; r = −0.48) were significantly correlated ( p ≤ 0.05) to on-ice acceleration and top speed, respectively. Conversely, none of the off-ice tests correlated with on-ice repeated shift performance, as measured by first gate, second gate, or total course fatigue; VJ ( r = 0.06; r = 0.13; r = 0.09), WRPP ( r = 0.06; r = 0.14; r = 0.10), or WRMP ( r = −0.10; r = −0.01; r = −0.01). Although conventional off-ice anaerobic power tests predict single bout on-ice acceleration and top speed, they neither predict the repeated shift ability of the player, nor are good markers for performance in ice hockey.
A Cross-Sectional Analysis of Late-Life Cardiovascular Factors and Their Relation to Clinically Defined Neurodegenerative Diseases
Dugger, Brittany N. , Malek‐Ahmadi, Michael , Monsell, Sarah E. , Kukull, Walter A. , Woodruff, Bryan K. , Reiman, Eric M. , Beach, Thomas G. , Wilson, Jeffrey R. , Dugger, Brittany N

Mayo Clinic

Alzheimer Disease & Associated Disorders | January 12, 2016 | Volume: 30 | Issue: 3 | Pages: 223-229

10.1097/wad.0000000000000138 | PMID 26756386 Get It

Studies have demonstrated associations between cardiovascular factors and Alzheimer disease (AD) with minimal focus on other neurodegenerative diseases. Utilizing cross-sectional data from 17,532 individuals in the National Alzheimer’s Coordinating Center, Uniform Data Set, we compared the presence of cardiovascular factors [body mass index (BMI), atrial fibrillation, hypertension, hyperlipidemia, and diabetes] in individuals carrying a diagnosis of Probable AD (ProbAD), Possible AD, vascular dementia, dementia with Lewy bodies (DLB), frontotemporal dementia, Parkinson disease, progressive supranuclear palsy, or corticobasal degeneration, with that of normals. Generalized linear mixed models were fitted with age at visit, gender, and cardiovascular factors as fixed effects and Alzheimer’s Disease Centers as random effects. In late life, only BMI of ProbAD and DLB patients was statistically significantly lower than that in normals (P–values <0.001). When accounting for colinearity within cardiovascular factors, a low BMI was a comorbidity of certain dementia etiologies as compared with normals. These data support a concept of disease-specific associations with certain cardiovascular factors.
A Case of Severe, Prolonged, Refractory Hypophosphatemia After Zoledronic Acid Administration
Clark, Sarah L. , Nystrom, Erin M.

Mayo Clinic

Journal of Pharmacy Practice | January 6, 2016 | Volume: 29 | Issue: 2 | Pages: 172-176

10.1177/0897190015624050 | PMID 26739479 Get It

Zoledronic acid (ZA) administration has been associated with electrolyte abnormalities, including hypocalcemia, hypomagnesemia, hypokalemia, and hypophosphatemia. We describe a case of severe, refractory hypophosphatemia in a patient who received ZA for hypercalcemia of malignancy (HCM). Little data are available that describe the incidence or degree of severity of hypophosphatemia that can occur following ZA administration. In addition, no formal recommendations exist to guide monitoring for or management of electrolyte derangements in the setting of bisphosphonate use. Our patient required daily, high-dose phosphorus replacement beginning day 4 following ZA administration. The average daily dose of phosphorus, including both intravenous and enteral administration, was highest in the first 2 weeks after ZA, averaging 77 mmol/d days 4 through 15, and does not include sources of phosphorus from the patient’s nutrition support. Despite this high amount of supplementation, which was well beyond what meets normal daily requirements and the amount expected to treat “usual” hypophosphatemia, the patient did not achieve sustained normal serum phosphorus levels for over 30 days after ZA. ZA is a favorable option for treating HCM because of its longer duration of action, potent serum calcium-lowering effects, and favorable safety profile. The risk of hypophosphatemia with ZA use is reviewed.
Paliperidone Palmitate Associated with Necrotizing Deep Tissue Infection and Sepsis Requiring Surgical Intervention
Leung, Jonathan G. , Kooda, Kirstin , Frazee, Erin N., Nelson, Sarah , Moore, Katherine M. , Kooda, Kirstin J, Frazee, Erin N., Leung, Jonathan G

Mayo Clinic

Case Reports in Psychiatry | December 30, 2015 | Volume: 2015 | Issue: No issue available | Pages: 1-3

10.1155/2015/364325 | PMID 26843999 Get It

Long-acting injectable antipsychotics provide the delivery of medication over an extended period of time requiring administration typically only every 2 to 4 weeks. The side effect profile of a long-acting injectable antipsychotic is predictable and similar to the oral formulation. However, injection site reactions may occur with this novel delivery system. The risk of an injection site reaction may be greater with the repeated administration of a lipophilic decanoate formulation and include pain, development of indurations, and fibrosis. Severe complications from injection site reactions have rarely been described in the literature with newer agents. We report the first case of a patient prescribed paliperidone palmitate every 3 weeks that developed severe sepsis requiring vasopressors and intubation due to delayed relayed recognition of a necrotizing infection at an injection site. Clinicians should be alerted to screen for injection site reactions when there is an unknown source infection in a patient receiving a long-acting injectable antipsychotic.
Standardizing the Definition of Biochemical Recurrence after Radical Prostatectomy—What Prostate Specific Antigen Cut Point Best Predicts a Durable Increase and Subsequent Systemic Progression?
Toussi, Amir , Stewart‐Merrill, Suzanne B., Boorjian, Stephen A. , Psutka, Sarah P. , Thompson, R. Houston, Frank, Igor, Tollefson, Matthew K. , Gettman, Matthew T., Carlson, Rachel E. , Rangel, Laureano J. , Karnes, R. Jeffrey , Psutka, Sarah P

Mayo Clinic

Journal of Urology | December 23, 2015 | Volume: 195 | Issue: 6 | Pages: 1754-1759

10.1016/j.juro.2015.12.075 | PMID 26721226 Get It

Use of Personalized Printed 3-Dimensional Kidney Models for Simulation before Nephron Sparing Surgery: Methodology and Examples from a Case Series
Gershman, Boris , Matsumoto, Jane M., King, Bernard F., Leibovich, Bradley C. , Psutka, Sarah P. , Kawashima, Akira , Morris, Jonathan M.

Mayo Clinic

Urology Practice | December 21, 2015 | Volume: 3 | Issue: 2 | Pages: 124-133

10.1016/j.urpr.2015.05.008 | PMID 37592473 Get It